NCT00423202View on ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

PHASE3CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

October 31, 2005

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

ambrisentan

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY